Friday, April 27, 2012
CytRx Corp., of Los Angeles, began a Phase II trial of INNO-2006 for pancreatic ductual adenocarcinomas. The open-label trial will enroll up to 27 patients to receive IV INNO-206 once every three weeks for eight cycles. The trial will assess objective tumor response, with secondary endpoints of complete and partial response, stable disease at four months and progression-free survival.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.